Given the established connection between psoriasis and metabolic syndrome, as well as the frequent coexistence of obesity and dyslipidemia in psoriatic patients, the observed association between gal-4 levels and BMI highlights its potential role as a molecular mediator bridging metabolic and inflammatory pathways. This evidence concerns the gene LGALS4 and obesity due to melanocortin 4 receptor deficiency.